About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

US Pharma Gians Bristol-Myers to Pay $15 Million to End Probe

by VR Sreeraman on September 30, 2007 at 11:23 AM
Font : A-A+

US Pharma Gians Bristol-Myers to Pay $15 Million to End Probe

Bristol-Myers Squibb will pay 515 million dollars to settle a probe into illegal kickbacks to doctors and fraudulent pricing of its drugs to government health programs, officials said Friday.

The Justice Department said the US pharmaceutical giant and its Apothecon subsidiary agreed to the payments to settle the civil allegations on drug marketing and pricing practices.

Advertisement

Bristol-Myers said the settlement covers the previously disclosed investigations that began several years ago. The company had agreed in principle to a settlement in December and to implement a five-year "corporate integrity agreement."

Government investigators alleged that Bristol-Myers from 2000 through mid-2003 paid "illegal remuneration to physicians and other health care providers to induce them to purchase BMS drugs," the Justice Department statement said.
Advertisement

The money was in the form of "consulting fees and expenses" to physicians and other health care providers as well as "travel to luxurious resorts."

From 1994 through 2001, according to investigators, Apothecon paid "illegal remuneration such as stocking allowances, price protection payments, market share payments, and free goods in order to induce its retail pharmacy and wholesaler customers to purchase its products."

In both cases, the government alleged that the company caused the submission of inflated and fraudulent claims to the federal health care programs.

"The integrity of our health care system rests on physicians being able to make decisions based on the best interests of their patients," said acting Attorney General Peter Keisler.

"This settlement reflects the Justice Department's strong commitment to holding drug companies accountable for devising and implementing fraudulent marketing and pricing schemes that undermine that decision-making process at the expense of federal health care programs for the poor and the elderly."

Bristol-Myers said in a separate statement it "is pleased to have resolved these matters from the past and is proud of its commitment to conduct business with the highest standards of integrity in its mission to extend and enhance human life."

Source: AFP
SRM/C
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity 

Recommended Reading
Western Pharma’s Outraged by Thai's Move to Import Heart Drug from India
Thailand's army-backed government said Wednesday it would import generic versions of popular heart ....
Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma
Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use